Stratec SE (SBS) - Net Assets
Based on the latest financial reports, Stratec SE (SBS) has net assets worth €237.32 Million EUR (≈ $277.45 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€443.38 Million ≈ $518.36 Million USD) and total liabilities (€206.06 Million ≈ $240.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Stratec SE's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €237.32 Million |
| % of Total Assets | 53.52% |
| Annual Growth Rate | 54.22% |
| 5-Year Change | 15.34% |
| 10-Year Change | 65.13% |
| Growth Volatility | 23478.91 |
Stratec SE - Net Assets Trend (2002–2025)
This chart illustrates how Stratec SE's net assets have evolved over time, based on quarterly financial data. See SBS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Stratec SE (2002–2025)
The table below shows the annual net assets of Stratec SE from 2002 to 2025. For live valuation and market cap data, see SBS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €237.32 Million ≈ $277.45 Million |
-2.15% |
| 2024-12-31 | €242.53 Million ≈ $283.55 Million |
+3.95% |
| 2023-12-31 | €233.33 Million ≈ $272.78 Million |
+3.62% |
| 2022-12-31 | €225.18 Million ≈ $263.26 Million |
+9.44% |
| 2021-12-31 | €205.76 Million ≈ $240.55 Million |
+19.25% |
| 2020-12-31 | €172.54 Million ≈ $201.72 Million |
+8.51% |
| 2019-12-31 | €159.01 Million ≈ $185.90 Million |
+4.47% |
| 2018-12-31 | €152.20 Million ≈ $177.94 Million |
-3.57% |
| 2017-12-31 | €157.84 Million ≈ $184.53 Million |
+9.82% |
| 2016-12-31 | €143.72 Million ≈ $168.02 Million |
+10.32% |
| 2015-12-31 | €130.28 Million ≈ $152.31 Million |
+16.27% |
| 2014-12-31 | €112.05 Million ≈ $131.00 Million |
+15.30% |
| 2013-12-31 | €97.18 Million ≈ $113.61 Million |
+5.65% |
| 2012-12-31 | €91.98 Million ≈ $107.54 Million |
+10.52% |
| 2011-12-31 | €83.23 Million ≈ $97.31 Million |
+15.79% |
| 2010-12-31 | €71.88 Million ≈ $84.03 Million |
+21.24% |
| 2009-12-31 | €59.29 Million ≈ $69.31 Million |
+18.81% |
| 2008-12-31 | €49.90 Million ≈ $58.34 Million |
+2.73% |
| 2007-12-31 | €48.58 Million ≈ $56.79 Million |
+21.03% |
| 2006-12-31 | €40.13 Million ≈ $46.92 Million |
+27.32% |
| 2005-12-31 | €31.52 Million ≈ $36.85 Million |
+103.80% |
| 2004-12-31 | €15.47 Million ≈ $18.08 Million |
+20.17% |
| 2003-12-31 | €12.87 Million ≈ $15.05 Million |
+115147.08% |
| 2002-12-31 | €11.17K ≈ $13.06K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Stratec SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5265433.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €170.34 Million | 71.78% |
| Common Stock | €12.16 Million | 5.12% |
| Other Comprehensive Income | €17.36 Million | 7.31% |
| Other Components | €37.46 Million | 15.79% |
| Total Equity | €237.32 Million | 100.00% |
Stratec SE Competitors by Market Cap
The table below lists competitors of Stratec SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aspo Oyj
HE:ASPO
|
$214.01 Million |
|
Kg Chemical
KO:001390
|
$214.15 Million |
|
Compagnie Du Mont-Blanc
PA:MLCMB
|
$214.33 Million |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
$214.35 Million |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
$213.94 Million |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
$213.87 Million |
|
T'way Air Co Ltd
KO:091810
|
$213.85 Million |
|
Immersion Corporation
NASDAQ:IMMR
|
$213.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stratec SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 242,533,000 to 237,320,000, a change of -5,213,000 (-2.1%).
- Net loss of 242,000 reduced equity.
- Dividend payments of 7,293,000 reduced retained earnings.
- Other comprehensive income increased equity by 17,359,000.
- Other factors decreased equity by 15,037,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-242.00K | -0.1% |
| Dividends Paid | €7.29 Million | -3.07% |
| Other Comprehensive Income | €17.36 Million | +7.31% |
| Other Changes | €-15.04 Million | -6.34% |
| Total Change | €- | -2.15% |
Book Value vs Market Value Analysis
This analysis compares Stratec SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 16017.10x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €0.00 | €18.50 | x |
| 2003-12-31 | €1.30 | €18.50 | x |
| 2004-12-31 | €1.54 | €18.50 | x |
| 2005-12-31 | €3.00 | €18.50 | x |
| 2006-12-31 | €3.53 | €18.50 | x |
| 2007-12-31 | €4.23 | €18.50 | x |
| 2008-12-31 | €4.38 | €18.50 | x |
| 2009-12-31 | €5.19 | €18.50 | x |
| 2010-12-31 | €6.16 | €18.50 | x |
| 2011-12-31 | €7.11 | €18.50 | x |
| 2012-12-31 | €7.83 | €18.50 | x |
| 2013-12-31 | €8.25 | €18.50 | x |
| 2014-12-31 | €9.47 | €18.50 | x |
| 2015-12-31 | €10.93 | €18.50 | x |
| 2016-12-31 | €12.04 | €18.50 | x |
| 2017-12-31 | €13.17 | €18.50 | x |
| 2018-12-31 | €12.65 | €18.50 | x |
| 2019-12-31 | €13.18 | €18.50 | x |
| 2020-12-31 | €14.20 | €18.50 | x |
| 2021-12-31 | €16.89 | €18.50 | x |
| 2022-12-31 | €18.50 | €18.50 | x |
| 2023-12-31 | €19.19 | €18.50 | x |
| 2024-12-31 | €19.95 | €18.50 | x |
| 2025-12-31 | €19.52 | €18.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stratec SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.10%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.87x
- Recent ROE (-0.10%) is below the historical average (465.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 9947.18% | 3.95% | 1313.10x | 1.92x | €1.11 Million |
| 2003 | 13.08% | 5.13% | 1.38x | 1.85x | €396.81K |
| 2004 | 17.96% | 7.09% | 1.53x | 1.66x | €1.23 Million |
| 2005 | 14.00% | 9.11% | 1.11x | 1.38x | €1.26 Million |
| 2008 | 12.29% | 9.08% | 0.97x | 1.40x | €1.14 Million |
| 2009 | 19.69% | 14.67% | 0.93x | 1.45x | €5.75 Million |
| 2010 | 18.14% | 12.22% | 1.08x | 1.38x | €5.85 Million |
| 2011 | 18.36% | 12.51% | 1.10x | 1.33x | €6.96 Million |
| 2012 | 15.19% | 11.41% | 1.00x | 1.32x | €4.77 Million |
| 2013 | 15.93% | 12.10% | 1.09x | 1.21x | €5.76 Million |
| 2014 | 17.64% | 13.65% | 1.05x | 1.23x | €8.56 Million |
| 2015 | 16.95% | 15.03% | 0.92x | 1.22x | €9.06 Million |
| 2016 | 13.62% | 10.58% | 0.72x | 1.79x | €5.20 Million |
| 2017 | 16.24% | 12.22% | 0.80x | 1.67x | €9.85 Million |
| 2018 | 5.89% | 4.78% | 0.68x | 1.81x | €-6.25 Million |
| 2019 | 9.08% | 6.52% | 0.74x | 1.88x | €-1.46 Million |
| 2020 | 14.59% | 10.07% | 0.75x | 1.92x | €7.92 Million |
| 2021 | 19.42% | 13.91% | 0.78x | 1.79x | €19.38 Million |
| 2022 | 12.98% | 10.64% | 0.69x | 1.77x | €6.70 Million |
| 2023 | 6.59% | 5.68% | 0.58x | 2.00x | €-7.96 Million |
| 2024 | 6.61% | 6.22% | 0.58x | 1.84x | €-8.23 Million |
| 2025 | -0.10% | -0.10% | 0.57x | 1.87x | €-23.97 Million |
Industry Comparison
This section compares Stratec SE's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $48,775,866,946
- Average return on equity (ROE) among peers: -38.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stratec SE (SBS) | €237.32 Million | 9947.18% | 0.87x | $213.94 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $16.74 Billion | 1.48% | 0.47x | $152.32K |
| BIORETEC OY (0TN) | $1.92 Million | -125.78% | 0.82x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.59 Million | -168.10% | 0.60x | $28.30 Million |
| Medtronic PLC (2M6) | $395.90 Million | 21.85% | 0.62x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.81 Billion | -73.53% | 0.02x | $319.35 Million |
| AVITA Medical Inc (51KB) | $115.66 Million | -22.98% | 0.09x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and softwar… Read more